Given the potential relevance for CAR T cell immunotherapy, we also examined pre- and postinfusion biopsies from a phase I/II trial testing a CD19-targeted CAR T cell product in relapsed/refractory (R/R) DLBCL (48) (Supplemental Table 5). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.